Profile
Jon Filderman is currently working as the Secretary & Director at Acceleron Pharma, Inc. since 2021.
Prior to this, he worked as a Director at Organon & Co. and as a Manager at Rosetta Inpharmatics LLC.
Jon Filderman active positions
Companies | Position | Start |
---|---|---|
ACCELERON PHARMA INC. | Director/Board Member | 2021-11-18 |
Former positions of Jon Filderman
Companies | Position | End |
---|---|---|
ORGANON & CO. | Director/Board Member | 2021-06-01 |
Rosetta Inpharmatics LLC
Rosetta Inpharmatics LLC BiotechnologyHealth Technology Rosetta Inpharmatics LLC designed and implemented DNA microarray gene expression systems. The company provided software for use in informational genomics. The company was founded in may 29, 2009 and was headquartered in Seattle, WA. | Corporate Officer/Principal | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
ORGANON & CO. | Health Technology |
Private companies | 2 |
---|---|
Rosetta Inpharmatics LLC
Rosetta Inpharmatics LLC BiotechnologyHealth Technology Rosetta Inpharmatics LLC designed and implemented DNA microarray gene expression systems. The company provided software for use in informational genomics. The company was founded in may 29, 2009 and was headquartered in Seattle, WA. | Health Technology |
Acceleron Pharma, Inc.
Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Jon Filderman